v3.26.1
Revenues (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Product and Geographic Area The following table represents total net revenues by product line:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
HIV$14,170 $14,398 $27,189 $27,298 
Sample Management Solutions (1)
9,875 9,855 18,933 18,965 
HCV3,393 4,126 6,056 8,459 
Other product and services revenues (2)
2,285 994 3,903 1,767 
COVID-19 (3)
1 28 19 489 
Risk Assessment Testing (4)
— 446 — 1,866 
Net product and services revenues$29,724 $29,847 $56,100 $58,844 
Non-product and services revenues (5)
915 1,395 2,464 2,329 
Net revenues$30,639 $31,242 $58,564 $61,173 
(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2) Includes Syphilis revenues and single order fulfillment.
(3) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(4) Includes substance abuse testing product revenues.
(5) Includes funded research and development contracts, royalty income and grant revenues.
The following table represents total net revenues by geographic area, based on the location of the customer:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
United States$20,235 $19,852 $38,907 $40,187 
Africa6,786 8,027 13,560 15,216 
Europe1,743 2,117 3,192 3,754 
Other regions1,875 1,246 2,905 2,016 
$30,639 $31,242 $58,564 $61,173 
Schedules of Concentration of Risk, by Risk Factor The following table represents customer concentration risk:
June 30,December 31,
Accounts Receivable20262025
Commercial customer (1)
14 %N/A
Commercial customer (1)
11 %15 %
(1) Each commercial customer is a different international distributor.
Schedule of Deferred Revenue
The following table represents deferred revenue recognized:
For the Three Months Ended June 30,For the Six Months Ended June 30,
Deferred Revenue Recognized2026202520262025
Accrued at beginning of year$148 $974 $1,109 $1,461